Ambivalence: A Key to Clinical Trial Participation?

被引:4
|
作者
Chilton, Janice A. [1 ]
Rasmus, Monica L. [1 ]
Lytton, Jay [2 ,3 ]
Kaplan, Charles D. [2 ]
Jones, Lovell A. [4 ]
Hurd, Thelma C. [5 ]
机构
[1] Texas Southern Univ, Pharm Adm & Adm Hlth Sci, Houston, TX 77004 USA
[2] Univ Southern Calif, Adult Mental Hlth & Wellnes, Los Angeles, CA USA
[3] Univ Southern Calif, Haimovitch Ctr Sci Human Serv, Los Angeles, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA
来源
FRONTIERS IN ONCOLOGY | 2018年 / 8卷
关键词
ambivalence; clinical trials; disparities; motivational interviewing; trust; HEALTH-CARE-SYSTEM; SHARED DECISION-MAKING; CANCER-PATIENTS; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; TRUST; DISTRUST; SUPPORT; INFORMATION; ATTITUDES;
D O I
10.3389/fonc.2018.00300
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Trust exerts a multidimensional influence at the interpersonal level in the clinical trials setting. Trust and distrust are dynamic states that are impacted, either positively or negatively, with each participant-clinical trials team interaction. Currently, accepted models of trust posit that trust and distrust coexist and their effects on engagement and retention in clinical trials are mediated by ambivalence. While understanding of trust has been informed by a robust body of work, the role of distrust and ambivalence in the trust building process are less well understood. Furthermore, the role of ambivalence and its relationship to trust and distrust in the clinical trials and oncology settings are not known. Ambivalence is a normal and uncomfortable state in the complex decision making process that characterizes the recruitment and active treatment phases of the clinical trials experience. The current review was conducted to understand the constructs of ambivalence as a mediator of trust and distrust among vulnerable, minority participants through different stages of the oncology clinical trials continuum, its triggers and the contextual factors that might influence it in the setting of minority participation in oncology clinical trials. In addition, the researchers have sought to link theory to clinical intervention by investigating the feasibility and role of Motivational Interviewing in different stages of the clinical trials continuum. Findings suggest that ambivalence can be processed and managed to enable a participant to generate a response to their ambivalence. Thus, recognizing and managing triggers of ambivalence, which include, contradictory goals, role conflicts, membership dualities, and supporting participants through the process of reducing ambivalence is critical to successfully managing trust. Contextual factors related to the totality of one's previous health-care experience, specifically among the marginalized or vulnerable, can contribute to interpersonal ambivalence. In addition, changes in information gathering as a moderator of interpersonal ambivalence may have enormous implications for gathering, assessing, and accepting health information. Finally, motivational Interviewing has widespread applications in healthcare settings, which includes enabling participants to navigate ambivalence in shared-decision making with their clinician, as well as executing changes in participant behavior. Ultimately, the Integrated Model of Trust can incorporate the role of therapeutic techniques like Motivational Interviewing in different stages of the clinical trials continuum. Ambivalence is a key component of clinical trial participation; like trust, ambivalence can be managed and plays a major role in the management of trust in interpersonal relationships over time. The management of ambivalence may play a major role in increasing clinical trial participation particularly among the marginalized or the vulnerable, who may be more susceptible to feelings of ambivalence.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Key issues for elderly patients contemplating clinical trial participation
    Carandang, Leslie
    Goldsack, Jennifer C.
    Sonnad, Seema S.
    [J]. JOURNAL OF WOMEN & AGING, 2016, 28 (05) : 412 - 417
  • [2] ON CLINICAL-TRIAL PARTICIPATION
    FISHER, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (11) : 1927 - 1930
  • [3] Minority Clinical Trial Participation
    不详
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (05) : 17N - 18N
  • [4] Trust in research physicians as a key dimension of randomized controlled trial participation in clinical addictions research
    Jaffe, Kaitlyn
    Nosova, Ekaterina
    DeBeck, Kora
    Hayashi, Kanna
    Milloy, M-J
    Richardson, Lindsey
    [J]. SUBSTANCE ABUSE, 2021, 42 (04) : 927 - 934
  • [5] APPLICATION OF PARTICIPATION IN CLINICAL PRACTICE: KEY ISSUES
    van de Velde, Dominique
    Coussens, Marieke
    De Baets, Stijn
    Sabbe, Lode
    Vanderstraeten, Guy
    Vlerick, Peter
    Van Malderen, Lien
    Gorus, Ellen
    De Vriendt, Patricia
    [J]. JOURNAL OF REHABILITATION MEDICINE, 2018, 50 (08) : 679 - +
  • [6] The unspoken benefit of participation in a clinical trial
    Schwarz, Konstantin
    Parasuraman, Sathish
    Singh, Satnam
    Horowitz, John
    Dawson, Dana K.
    Frenneaux, Michael P.
    [J]. CLINICAL MEDICINE, 2021, 21 (06) : E645 - E647
  • [7] Race and HIV Clinical Trial Participation
    DeFreitas, Donna
    [J]. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2010, 102 (06) : 493 - 499
  • [8] Equal opportunities for clinical trial participation
    不详
    [J]. LANCET HAEMATOLOGY, 2021, 8 (08): : E535 - E535
  • [9] PERCEPTIONS OF REIMBURSEMENT FOR CLINICAL TRIAL PARTICIPATION
    Breitkopf, Carmen Radecki
    Loza, Melissa
    Vincent, Kathleen
    Moench, Thomas
    Stanberry, Lawrence R.
    Rosenthal, Susan L.
    [J]. JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 2011, 6 (03) : 31 - 38
  • [10] Patient satisfaction with clinical trial participation
    Verheggen, FWSM
    Nieman, FHM
    Reerink, N
    Kok, GJ
    Kok, J
    [J]. INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 1998, 10 (04) : 319 - 330